Avacta previews AVA6103 pharmacokinetic data as sustained-release cancer drug faces first human test
Avacta’s next AVA6103 data will test sustained exatecan release in cancer patients. Read what the FOCUS-01 results could mean for its platform.
Features & Analysis
Pharma & Biotech
Why Tempus’ tumor-only xT CDx approval could matter for precision oncology testing
Find out how Tempus’ tumor-only xT CDx FDA approval could expand precision oncology testing and reshape solid tumor profiling.
Medical Devices & Diagnostics
Why Tempus AI’s Lens upgrade matters for precision oncology drug development
Tempus AI expands Lens with agentic AI for oncology drug development. Find out how it could reshape trials, evidence generation and biopharma R&D.
Pharma & Biotech
How Tempus AI and Daiichi Sankyo are using real-world data to reshape antibody-drug conjugate development
Tempus AI and Daiichi Sankyo are using multimodal AI to refine ADC trial strategy and biomarker discovery. Read what this could change next.